BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia

被引：0

作者：

Stone, Richard M. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Leukemia Div, Boston, MA 02115 USA

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 04期

关键词：

CHEMOTHERAPY; AML;

D O I：

10.3324/haematol.2020.274753

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：931 / 932

页数：2

共 8 条

[1] Targeting FLT3 mutations in AML: review of current knowledge and evidence [J].

Daver, Naval ;

Schlenk, Richard F. ;

Russell, Nigel H. ;

Levis, Mark J. .

LEUKEMIA, 2019, 33 (02) :299-312

[2] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[3] A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia [J].

Lee, Lauren ;

Hizukuri, Yoshiyuki ;

Severson, Paul ;

Powell, Benjamin ;

Zhang, Chao ;

Ma, Yan ;

Narahara, Maiko ;

Sumi, Hiroyuki ;

Hernandez, Daniela ;

Rajkhowa, Trivikram ;

Bollag, Gideon ;

Levis, Mark .

HAEMATOLOGICA, 2021, 106 (04) :1022-1033

[4] Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia [J].

McMahon, Christine M. ;

Ferng, Timothy ;

Canaani, Jonathan ;

Wang, Eunice S. ;

Issette, Jennifer J. D. Morr ;

Eastburn, Dennis J. ;

Pellegrino, Maurizio ;

Durruthy-Durruthy, Robert ;

Watt, Christopher D. ;

Asthana, Saurabh ;

Lasater, Elisabeth A. ;

DeFilippis, RosaAnna ;

Peretz, Cheryl A. C. ;

McGary, Lisa H. F. ;

Deihimi, Safoora ;

Logan, Aaron C. ;

Luger, Selina M. ;

Shah, No P. ;

Carroll, Martin ;

Smith, Catherine C. ;

Perl, Alexander E. .

CANCER DISCOVERY, 2019, 9 (08) :1050-1063

[5] Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML [J].

Perl, A. E. ;

Martinelli, G. ;

Cortes, J. E. ;

Neubauer, A. ;

Berman, E. ;

Paolini, S. ;

Montesinos, P. ;

Baer, M. R. ;

Larson, R. A. ;

Ustun, C. ;

Fabbiano, F. ;

Erba, H. P. ;

Di Stasi, A. ;

Stuart, R. ;

Olin, R. ;

Kasner, M. ;

Ciceri, F. ;

Chou, W-C ;

Podoltsev, N. ;

Recher, C. ;

Yokoyama, H. ;

Hosono, N. ;

Yoon, S-S ;

Lee, J-H ;

Pardee, T. ;

Fathi, A. T. ;

Liu, C. ;

Hasabou, N. ;

Liu, X. ;

Bahceci, E. ;

Levis, M. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) :1728-1740

[6] The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition [J].

Shi, Junwei ;

Vakoc, Christopher R. .

MOLECULAR CELL, 2014, 54 (05) :728-736

[7] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation [J].

Stone, R. M. ;

Mandrekar, S. J. ;

Sanford, B. L. ;

Laumann, K. ;

Geyer, S. ;

Bloomfield, C. D. ;

Thiede, C. ;

Prior, T. W. ;

Doehner, K. ;

Marcucci, G. ;

Lo-Coco, F. ;

Klisovic, R. B. ;

Wei, A. ;

Sierra, J. ;

Sanz, M. A. ;

Brandwein, J. M. ;

de Witte, T. ;

Niederwieser, D. ;

Appelbaum, F. R. ;

Medeiros, B. C. ;

Tallman, M. S. ;

Krauter, J. ;

Schlenk, R. F. ;

Ganser, A. ;

Serve, H. ;

Ehninger, G. ;

Amadori, S. ;

Larson, R. A. ;

Doehner, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (05) :454-464

[8] Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase [J].

Yang, Xiaochuan ;

Sexauer, Amy ;

Levis, Mark .

BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (01) :61-72

← 1 →